Back to Registry

Dihexa

Also known as: N-Hexanoyl-Tyr-Ile-(6)-amino hexanoic amide

Compounding Eligible

Molecular Formula

C27 H44 N4 O5

Molecular Weight

504.66 Da

Half-Life

12.68 days (IV, murine); 8.83 days (IP, murine); unknown in humans

Sequence

N-hexanoyl-YI-Ahx-NH2

Clinical Applications & Evidence

Mechanism of Action

Dihexa binds with picomolar affinity (Kd ~65 pM) to hepatocyte growth factor (HGF), facilitating HGF dimerization and subsequent activation of the c-Met receptor. This interaction initiates downstream intracellular cascades, notably the PI3K/AKT and mTOR signaling pathways, which drive dendritic arborization, the formation of functional synapses, and anti-inflammatory microglial modulation.

Investigated Uses

  • Alzheimer's disease
  • Age-related cognitive decline
  • Traumatic brain injury recovery
  • Neuroplasticity enhancement
  • Dementia prevention research
Animal Models Only

Regulatory & Safety Status

FDA Status

Compounding Eligible

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

Largely unknown in humansHeadache (anecdotal)Overstimulation (anecdotal)

Contraindications

  • Active malignancy or prior history of cancer
  • Uncharacterized precancerous lesions
  • Pregnancy and breastfeeding

Drug Interactions

  • Unknown — limited human data
  • Theoretical interaction with ACE inhibitors

Citations & Clinical Trials

PubMed Dihexa — HGF/c-Met Procognitive Mechanism